Article
Multidisciplinary Sciences
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xichun Hu
Summary: Platinum in combination with gemcitabine is recommended for the treatment of metastatic triple-negative breast cancer. In a randomized controlled trial, nab-paclitaxel/cisplatin was compared with gemcitabine/cisplatin in mTNBC patients. The study found that nab-paclitaxel/cisplatin significantly improved progression-free survival, objective response rate, and overall survival compared to gemcitabine/cisplatin. However, there were higher incidences of neuropathy in the nab-paclitaxel/cisplatin group and thrombocytopenia in the gemcitabine/cisplatin group.
NATURE COMMUNICATIONS
(2022)
Article
Medicine, Research & Experimental
Jing Li, Xiaoqin Xu, Xiting Peng
Summary: This study investigated the mechanism of cisplatin resistance in triple-negative breast cancer (TNBC). The results revealed that NDC80 was a cisplatin-resistant gene and its expression differed between cisplatin-sensitive and resistant cells. NDC80 was found to be overexpressed in TNBC tissues and increased after cisplatin treatment. Moreover, NDC80 overexpression promoted the viability and proliferation of TNBC cells and enhanced their resistance to cisplatin. The study also identified potential pathways associated with cisplatin resistance.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Article
Oncology
Eve Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori Goldstein, Debu Tripathy, Ursa A. Brown-Glaberman, Thu-Tam Huynh, Christopher S. Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobagyi
Summary: PARP inhibitors are effective in germline BRCA1/2-mutated metastatic breast cancer. This study demonstrates that adding veliparib to cisplatin improves progression-free survival in patients with BRCA-like metastatic triple-negative breast cancer.
Article
Medicine, General & Internal
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Maitri Kalra, Yan Tong, David R. Jones, Tom Walsh, Michael A. Danso, Cynthia X. Ma, Paula Silverman, Mary-Claire King, Sunil S. Badve, Susan M. Perkins, Kathy D. Miller
Summary: In this study, the impact of DNA-damaging chemotherapy alone or with PARP inhibition in high-risk postoperative TNBC/BRCAmut patients was investigated. The addition of low-dose rucaparib to cisplatin did not improve 2-year disease-free survival or increase the toxicity of cisplatin in this high-risk population. Genetic testing was found to be underutilized in identifying deleterious mutations.
Review
Medicine, General & Internal
Shuanghe Li, Chongyang Bao, Lingli Huang, Ji-Fu Wei
Summary: TNBC is a highly invasive and metastatic form of breast cancer with poor prognosis. Standard chemotherapies are ineffective for metastatic TNBC due to lack of expression of certain receptors. However, new chemotherapy drugs, targeted drugs, and immunotherapy drugs offer promising treatment options. Pharmacists play a crucial role in drug selection, management, and evaluation.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cell Biology
Yuzhu Qi, Meifang Li, Shaozhong Li, De Zeng, Yingsheng Xiao, Jiwei Li, Qianqian Ye, Edwin Bremer, Guo-jun Zhang
Summary: This study explored the molecular mechanisms of chemoresistance in triple-negative breast cancer (TNBC) and found that Notch1 and CD73 were associated with poor clinical outcome in cisplatin-treated patients. Further experiments revealed that Notch1 regulated CD73 expression by directly binding to the CD73 promoter. These findings suggest that CD73 is a direct downstream target of Notch1 in mediating cisplatin resistance in TNBC.
CELL DEATH DISCOVERY
(2023)
Editorial Material
Oncology
Priyanka Sharma
Summary: Pathologic response is an important tool for optimizing the escalation and deescalation of adjuvant treatment. Neoadjuvant carboplatin-taxane combination shows promise as a chemotherapy deescalation strategy for triple-negative breast cancer. However, several key points, including trial design/patient selection, response biomarkers, role of immunotherapy, and patient advocate input, need to be carefully considered for the advancement of neoadjuvant chemotherapy deescalation investigations.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Honglin Yan, Bin Luo, Xiaoyan Wu, Feng Guan, Xinxin Yu, Lina Zhao, Xiaokang Ke, Juan Wu, Jingping Yuan
Summary: The study revealed that cisplatin induces pyroptosis in triple-negative breast cancer cells through activation of the MEG3/NLRP3/caspase-1/GSDMD pathway, leading to its anti-tumor effects. This finding may contribute to the development of new therapeutic strategies for TNBC.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Review
Nanoscience & Nanotechnology
Siyan Liu, Jing Li, Lin Gu, Kunzhe Wu, Hua Xing
Summary: Chemoimmunotherapy shows promise for treating TNBC, but challenges remain in improving efficacy and reducing side effects.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Review
Pharmacology & Pharmacy
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Summary: Triple negative breast cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptors. The survival rate for TNBC is generally lower than other subtypes. Chemotherapy is the most common treatment option, but resistance to drugs and off-target toxicity pose challenges. Researchers, clinicians, and pharmaceutical companies must collaborate to develop effective treatments for TNBC. Nanotechnology has shown promise as a potential solution for improving TNBC treatment.
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Ji-Yeon Kim, Sabin Park, Eun Yoon Cho, Jeong Eon Lee, Hae Hyun Jung, Byung Joo Chae, Seok Won Kim, Seok Jin Nam, Soo Youn Cho, Yeon Hee Park, Jin Seok Ahn, Semin Lee, Young-Hyuck Im
Summary: This study compared the genetic characteristics of apocrine carcinoma, a rare subtype of breast cancer, with triple negative breast cancer (TNBC) with low Ki-67 expression (LK-TNBC). The most frequently mutated driver gene in apocrine carcinoma was TP53, followed by PIK3CA, ZNF717, and PIK3R1. Apocrine carcinoma exhibited defective DNA mismatch repair and APOBEC activity-associated mutational signatures, and had better five-year disease-free survival and overall survival rates compared to LK-TNBC.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2023)
Article
Oncology
Juan Luis Gomez Marti, Colin H. Beckwitt, Amanda M. Clark, Alan Wells
Summary: The study examined the effects of atorvastatin on chemotherapy for mTNBC through animal models and clinical correlations. Atorvastatin was found to have additive effects with doxorubicin targeting liver metastases, and the combination of atorvastatin and chemotherapy led to increased cell death in dormant cancer cells.
BRITISH JOURNAL OF CANCER
(2021)
Review
Engineering, Biomedical
Pallabita Chowdhury, Upasana Ghosh, Kamalika Samanta, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Summary: Management of aggressive breast cancer, particularly TNBC, remains challenging despite advances in treatment. New therapies like atezolizumab, olaparib, and sacituzumab show limited survival benefits. Current research aims to improve treatment strategies by enhancing bioavailability, targetability, and reducing toxicity for better therapeutic outcomes.
BIOACTIVE MATERIALS
(2021)